PURPOSE OF REVIEW: In this review, we present recent clinical and urodynamic data on transurethral photoselective vaporization of the prostate, and report on the recent introduction of the 120 W GreenLight laser (GLL) high-performance system. RECENT FINDINGS: Published studies provide substantial evidence that photoselective prostate vaporization is an efficacious treatment for lower urinary tract symptoms caused by benign prostatic hyperplasia. Recent studies confirm improved urodynamic findings following GLL treatment. Moreover, it can be used safely in high-risk patients (e.g. those on anticoagulant medication and patients with cardiopulmonary diseases), and has been proposed as an alternative to prostate enucleation for larger glands. Depending on the reimbursement system in different countries, it can be a cost-effective procedure. The introduction of the 120 W high-performance system GLL does, however, place distinct demands on training and operative schemes. SUMMARY: The clinical results of GreenLight prostate vaporization are equivalent to those following transurethral resection of the prostate, with reduced operative risks, even for the high-risk patient. These clinical benefits have been confirmed by improved urodynamic parameters. The potential advantages of the new 120 W high-performance system GLL are yet to be unequivocally proven in larger randomized trials.
PURPOSE OF REVIEW: In this review, we present recent clinical and urodynamic data on transurethral photoselective vaporization of the prostate, and report on the recent introduction of the 120 W GreenLight laser (GLL) high-performance system. RECENT FINDINGS: Published studies provide substantial evidence that photoselective prostate vaporization is an efficacious treatment for lower urinary tract symptoms caused by benign prostatic hyperplasia. Recent studies confirm improved urodynamic findings following GLL treatment. Moreover, it can be used safely in high-risk patients (e.g. those on anticoagulant medication and patients with cardiopulmonary diseases), and has been proposed as an alternative to prostate enucleation for larger glands. Depending on the reimbursement system in different countries, it can be a cost-effective procedure. The introduction of the 120 W high-performance system GLL does, however, place distinct demands on training and operative schemes. SUMMARY: The clinical results of GreenLight prostate vaporization are equivalent to those following transurethral resection of the prostate, with reduced operative risks, even for the high-risk patient. These clinical benefits have been confirmed by improved urodynamic parameters. The potential advantages of the new 120 W high-performance system GLL are yet to be unequivocally proven in larger randomized trials.
Authors: D Batura; I Sahibzada; J Elkabir; O Feyisetan; V Izegbu; G Hellawell; J Webster Journal: Ann R Coll Surg Engl Date: 2014-07 Impact factor: 1.891
Authors: Woong Jin Bae; Sun Gook Ahn; Jun Ho Bang; Jang Ho Bae; Yong Sun Choi; Su Jin Kim; Hyuk Jin Cho; Sung Hoo Hong; Ji Youl Lee; Tae-Kon Hwang; Sae Woong Kim Journal: Korean J Urol Date: 2013-01-18